地加瑞克4个月与10个月诱导方案对间歇性雄激素剥夺治疗间歇期的影响
这项前瞻性随机开放标签Ⅱ期多中心研究纳入90例根治性局部治疗后生化复发且骨扫描阴性的前列腺癌患者,随机接受每月地加瑞克4个月或10个月诱导治疗。两组停药间歇期时长(HR 1.51,95%CI 0.60-3.84,p=0.38)及睾酮恢复时间均无差异,4个月组治疗结束时生活质量受影响更小。
要点
- 4个月与10个月地加瑞克诱导方案的停药间歇期时长无显著差异
- 两组睾酮恢复至≥8.0 nmol/l的时间无统计学差异(p=0.8392)
- 4个月方案治疗结束时对生活质量的负面影响小于10个月方案
核心结论
- 在生化复发后以地加瑞克启动间歇性雄激素剥夺治疗的男性中,4个月与10个月诱导治疗在停药间歇期时长或睾酮恢复率上均无差异。
研究设计与样本
- 前瞻性、随机、开放标签Ⅱ期多中心研究,共随机90例患者,其中4个月组43例、10个月组47例。
- 研究对象为前列腺癌局部治疗后生化复发且骨扫描阴性的男性;地加瑞克首剂240 mg,后续每月80 mg。
- 生活质量采用I-PSS、PAS-SFI与FACT-P评估。
主要发现
- 两组停药间歇期时长无差异(HR 1.51,95%CI 0.60-3.84,p=0.38)。
- 睾酮恢复至8.0 nmol/l或以上的 actuarial 中位时间在10个月组为8.05个月(95%CI 4.34-39.89),4个月组为6.24个月(95%CI 5.45-15.90),log rank检验p=0.8392。
- 两组睾酮恢复率无差异;年龄小于65岁者停药间歇期与睾酮恢复时间均明显更短。
- 4个月组治疗结束时对生活质量的不良影响小于10个月组。
关键数值与推荐
- 停药间歇期比较:HR 1.51,95%CI 0.60-3.84,p=0.38。
- 睾酮恢复至≥8.0 nmol/l的中位时间:10个月组8.05个月(95%CI 4.34-39.89),4个月组6.24个月(95%CI 5.45-15.90),p=0.8392。
- 地加瑞克给药方案:首剂240 mg,后续每月80 mg。
临床怎么用
- 对于局部治疗后生化复发、拟行间歇性雄激素剥夺治疗者,4个月诱导方案与10个月方案在停药间歇期和睾酮恢复上未见差异。
- 4个月方案治疗结束时生活质量影响更小,可作为缩短诱导疗程的参考。
- 年龄小于65岁者停药间歇期与睾酮恢复时间更短,治疗随访中需考虑年龄因素。
局限性
- 原文摘要未报告具体局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Clinical trials in men initiating intermittent androgen deprivation therapy have used a range of induction durations between 3 and 12 months. We sought to determine whether the duration of induction androgen deprivation therapy would influence the duration of the off treatment interval and the recovery of serum testosterone. MATERIALS AND METHODS: This was a prospective, randomized, open label study. Men with biochemical recurrence after local therapy for prostate cancer and a negative bone scan were randomized to 4 and 10 months of monthly degarelix. The first dose was 240 mg and subsequent doses were 80 mg per month. Quality of life was evaluated by the I-PSS (International Prostate Symptom Score), the PAS-SFI (Problem Assessment Scale of the Sexual Function Index) and the FACT-P (Functional Assessment of Cancer Therapy-Prostate). RESULTS: A total of 90 patients were randomized, including 43 to 4 months and 47 to 10 months of treatment. There was no difference in any relevant baseline laboratory parameter, including prostate specific antigen and testosterone. There was no difference between the 2 treatment groups in time off treatment (HR 1.51, 95% CI 0.60-3.84, p = 0.38). Actuarial median time to testosterone recovery to 8.0 nmol/l or greater was 8.05 months (95% CI 4.34-39.89) in the 10-month treatment arm and 6.24 months (95% CI 5.45-15.90) in the 4-month treatment arm. The log rank test showed no statistical significance between the 2 treatment groups in time to testosterone recovery (p = 0.8392). There was no difference in the testosterone recovery rate between the 2 arms. Men younger than 65 years had a considerably shorter interval off treatment and time to testosterone recovery. There was a lesser adverse effect on quality of life at the end of treatment in the 4-month than in the 10-month arm. CONCLUSIONS: In men with biochemical recurrence who initiated intermittent androgen deprivation therapy with degarelix no difference was observed in the duration of the off treatment interval or the rate of testosterone recovery whether they received 4 or 10 months of induction androgen deprivation therapy.
引用
- Klotz L, Loblaw A, Siemens R, et al. A Phase II, Randomized, Multicenter Study Comparing 10 Months versus 4 Months of Degarelix Therapy in Prolonging the Off Treatment Interval in Men with Localized Prostate Cancer Receiving Intermittent Androgen Deprivation Therapy for Biochemical Recurrence following Radical Local Therapy. J Urol. 2018. PMID: 29534997. doi:10.1016/j.juro.2018.03.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。